New LaunchJun 30, 2026, 09:17 AM
Arcutis Launches Virtual Health Platform for ZORYVE Access
AI Summary
Arcutis Biotherapeutics, Inc. announced the launch of a new virtual health platform aimed at expanding access to its ZORYVE (roflumilast) portfolio for chronic inflammatory skin diseases. This platform connects individuals with independent, board-certified dermatologists through a streamlined digital experience, offering an additional pathway to care for conditions like eczema, seborrheic dermatitis, and plaque psoriasis. It is designed to complement traditional in-office care by reducing barriers to specialist treatment and facilitating access to ZORYVE where appropriate.
Key Highlights
- Arcutis launched a new virtual health platform to expand access to its ZORYVE portfolio.
- The platform connects eligible individuals with independent, board-certified dermatologists.
- It targets patients with eczema, seborrheic dermatitis, and plaque psoriasis.
- The service offers a streamlined digital experience for evaluation and treatment discussions.
- Prescriptions are coordinated through a national pharmacy hub, including insurance support and home delivery.
- The platform complements traditional in-office dermatology care, reducing access barriers.
Price Impact
More from ARQT